Clozaril (Clozapine)

Generic Name

Clozapine

Brand Names

Clozaril, Versacloz

FDA approval date: July 08, 1999

Classification: Atypical Antipsychotic

Form: Tablet, Suspension

What is Clozaril (Clozapine)?

Reduction in the Risk of Recurrent Suicidal Behavior in Schizophrenia or Schizoaffective Disorder CLOZARIL is indicated for reducing the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder who are judged to be at chronic risk for re-experiencing suicidal behavior, based on history and recent clinical state. Suicidal behavior refers to actions by a patient that put him/herself at risk for death. The effectiveness of CLOZARIL in reducing the risk of recurrent suicidal behavior was demonstrated over a two-year treatment period in the InterSePT™ trial [see Clinical Studies ( 1. Treatment-Resistant Schizophrenia CLOZARIL is indicated for the treatment of severely ill patients with schizophrenia who fail to respond adequately to standard antipsychotic treatment. Because of the risks of severe neutropenia and of seizure associated with its use, CLOZARIL should be used only in patients who have failed to respond adequately to standard antipsychotic treatment [see Warnings and Precautions. CLOZARIL is an atypical antipsychotic indicated for: Treatment-resistant schizophrenia. Efficacy was established in an active-controlled study.

Approved To Treat

Schizophrenia

Top Global Experts

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Related Clinical Trials

Switching From Twice-Daily to Once-Daily Clozapine Dosing in Schizophrenia: A Pilot, Double-Blind, Randomized Controlled Trial

Who is this study for: Adult patients with schizophrenia

Enrollment Status: Recruiting

Publish Date: August 25, 2026

Intervention Type: Drug

Study Drug: Clozapine

Study Phase: Phase 4

Summary: Plasma half-life has routinely been used to establish the dosing schedule of antipsychotics; for example, it is recommended that agents with a short plasma half-life be administered multiple times per day. However, to date, several randomized controlled trials (RCTs) have shown no differences in clinical outcomes between once- and twice-daily dosing of various antipsychotics, suggesting that once-...

Biomarkers to Enhance Early Schizophrenia Treatment

Enrollment Status: Recruiting

Publish Date: July 31, 2026

Intervention Type: Drug

Study Phase: Phase 4

Summary: This study is recruiting participants who are experiencing a first episode of psychosis and who have certain genetic factors that may make them respond better to certain medications that are used to treat people with psychosis.

A Study of the Safety and Tolerability of GA in the Treatment of Patients With Refractory Neuropathic Pain

Enrollment Status: Recruiting

Publish Date: July 31, 2026

Intervention Type: Genetic

Study Phase: Early Phase 1

Summary: Previous studies have shown that the anterior cingulate cortex is involved in the regulation of pain and its associated negative emotions, that pyramidal neurons are highly excitable in chronic neuropathic pain conditions, and that silencing of pyramidal neurons can eliminate pain. The aim of this study was to evaluate the safety, tolerability, and efficacy of intracranial injection of GA (contain...

View All Clinical Trials